A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7497372 in Participants With Diabetic Macular Edema (DME)

Inclusion Criteria:

• Diagnosis of diabetes mellitus (type 1 or type 2), as defined by the world healthorganization (WHO) and/or American Diabetes Association

• Participant consents to AH collection

• Collection of > 90 microlitres (µL) AH (at each visit required per schedule ofactivities [SoA]) if deemed feasible and safe by the Investigator.

• Macular thickening secondary to DME involving the center of the fovea with CST >= 325 µm at screening

• Decreased BCVA primarily due to DME with ETDRS score of 78 to 19 letters (bothinclusive) at screening

• Adequately clear ocular media and adequate pupillary dilation to allow acquisitionof good quality retinal images

• Diagnosis of non-proliferative DR

• Treatment-naive and Pre-treated participants after washout

Exclusion Criteria:

• Any major illness or major surgical procedure ≤ 4 weeks before Day 1

• Any febrile illness and associated sequelae ≤ 1 week prior to Day 1

• Active cancer ≤ 1 year prior to Day 1

• Cerebral vascular accident (including stroke and transient ischemic attack) ormyocardial infarction ≤ 24 weeks prior to Day 1

• HbA1c ≥ 12% at screening

• Any panretinal photocoagulation or macular laser photocoagulation treatment prior toDay 1

• History of vitreoretinal surgery/pars plana vitrectomy

• Any cataract surgery within 12 weeks prior to Day 1 or any planned surgery duringthe study

• History of any glaucoma surgery including laser glaucoma procedures

• Uncontrolled glaucoma

• Any active intra- or periocular infection on Day 1

• Any active or history of Intraocular inflammation

• Intravitreal treatment with an anti-IL-6 (e.g., vamikibart) or anti-IL-6 receptortreatment at any time

• Any proliferative DR